This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AdaptHealth Corp. (AHCO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. LMAT: Which Stock Is the Better Value Option?
AHCO vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. SYK: Which Stock Is the Better Value Option?
5 Valuable Price-to-Book Stocks to Add to Your Portfolio
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks that have high-growth prospects. ASE Technology Holding (ASX), AdaptHealth Corp. (AHCO), ICL Group (ICL), Conn's (CONN) and Atlas Corp. (ATCO) are some such picks.
Can AdaptHealth (AHCO) Stock Continue to Grow Earnings?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AdaptHealth (AHCO).
Does AdaptHealth Corp. (AHCO) Have the Potential to Rally 60% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for AdaptHealth Corp. (AHCO) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AHCO or PETQ: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. PETQ: Which Stock Is the Better Value Option?
AdaptHealth Corp. (AHCO) Q3 Earnings Miss Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -41.18% and 2.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AdaptHealth Corp. (AHCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AdaptHealth Corp. (AHCO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -137.93% and 7.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AdaptHealth Corp. (AHCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AdaptHealth Corp. (AHCO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -29.17% and -0.57%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AHCO vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. SYK: Which Stock Is the Better Value Option?
AdaptHealth (AHCO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AdaptHealth (AHCO) has been struggling lately, but the selling pressure may be coming to an end soon
Company News for Mar 5, 2021
by Zacks Equity Research
Companies in The news Are: KR,MEI,AHCO,PRPL
AdaptHealth Corp. (AHCO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of 92.31% and 6.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Enhances Core Business With Buyout
by Zacks Equity Research
Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.
Integra (IART) Acquires Acell, Focuses on Regenerative Space
by Zacks Equity Research
The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.
Globus Medical (GMED) US Spine Grows, Pricing Pressure Stays
by Zacks Equity Research
Globus Medical's (GMED) recent product launches are seeing tremendous uptake.
Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens
by Zacks Equity Research
Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.
PerkinElmer (PKI) Receives FDA EUA for Asymptomatic Testing
by Zacks Equity Research
PerkinElmer's (PKI) RT-PCR assay to test individuals without COVID-19 symptoms acts as prime factor in controlling the spread.
Rockwell Medical (RMTI) Looks Good: Stock Adds 5.9% in Session
by Zacks Equity Research
Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Neogen (NEOG) Launches Dairy Toxin Detection Test Reveal Q+
by Zacks Equity Research
Neogen's (NEOG) new test can detect cancer causing aflatoxin M1 in milk within a range of 150-600 parts per trillion (ppt).
Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax
by Zacks Equity Research
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Company News for Dec 2, 2020
by Zacks Equity Research
Companies In The News Are: TSLA, KSS, AHCO, XOM